Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bluebird bio, Inc.    BLUE

BLUEBIRD BIO, INC.

(BLUE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 41.88, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 37.84 support.
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
BLUEBIRD BIO, INC.-51.41%2 830
GILEAD SCIENCES, INC.-7.28%75 525
VERTEX PHARMACEUTICALS-1.12%56 298
REGENERON PHARMACEUTICALS34.79%53 416
WUXI APPTEC CO., LTD.55.32%38 761
BIONTECH SE200.68%24 529
BEIGENE, LTD.54.55%23 352
GENMAB A/S49.17%23 080
ARGENX SE52.37%12 308
MYOKARDIA, INC.208.58%11 993
-
HUALAN BIOLOGICAL ENGINEERI..52.60%11 716
MIRATI THERAPEUTICS, INC.72.99%11 233
SAREPTA THERAPEUTICS, INC.4.70%10 662
NEUROCRINE BIOSCIENCES, INC..-12.90%8 951
ASCENDIS PHARMA A/S14.49%8 508
ULTRAGENYX PHARMACEUTICAL I..178.34%7 865
More Results
Financials (USD)
Sales 2020 260 M - -
Net income 2020 -594 M - -
Net cash 2020 1 233 M - -
P/E ratio 2020 -4,30x
Yield 2020 -
Capitalization 2 830 M 2 830 M -
EV / Sales 2020 6,15x
EV / Sales 2021 13,7x
Nbr of Employees 1 171
Free-Float 99,5%
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes